Notable 52-Week Highs and Lows 9/26: (ARRY) (GWPH) (ARIA) High; (ACOR) (GLF) (MNKD) Low

September 26, 2016 2:27 PM EDT

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

52-Week High:
  • Array BioPharma (Nasdaq: ARRY) $6.27. Array BioPharma and Pierre Fabre jointly announced top-line results from Part 1 of the Phase 3 COLUMBUS (Combined LGX818 Used with MEK162 in BRAF Mutant Unresectable Skin Cancer) study evaluating LGX818 (encorafenib), a BRAF inhibitor, and MEK162 (binimetinib), a MEK inhibitor, in patients with BRAF-mutant advanced, unresectable or metastatic melanoma. The study met its primary endpoint, significantly improving progression free survival (PFS) compared with vemurafenib, a BRAF inhibitor, alone.

  • GW Pharmaceuticals plc (Nasdaq: GWPH) $126.47. GW Pharmaceuticals announces positive results of the second randomized, double-blind, placebo-controlled Phase 3 clinical trial of its investigational medicine Epidiolex (cannabidiol or CBD) for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), a rare and severe form of childhood-onset epilepsy.

  • ARIAD Pharmaceuticals (Nasdaq: ARIA) $13.98. Leerink Partners initiates coverage on ARIAD Pharma with a Outperform rating and a price target of $20.
52-Week Low:
  • Acorda Therapeutics, Inc. (Nasdaq: ACOR) $22.92. The Arbitral Tribunal appointed by the Redemption Committee of the Finland Chamber of Commerce has today confirmed that Acorda Therapeutics, Inc. (Nasdaq: ACOR) has the right to redeem the minority shares in Biotie Therapies Corp. and that Acorda has the right to obtain title to the minority shares by lodging a security approved by the Arbitral Tribunal for the payment of the redemption price and the interest accruing thereon.

  • Gulfmark Offshore Inc. (NYSE: GLF) $1.55. LSC Communications Inc. and Donnelley Financial Solutions Inc. will be added to the S&P SmallCap 600 after the close of trading on Friday, September 30 replacing Gulfmark Offshore Inc. and Bonanza Creek Energy Inc. respectively, which will be removed from the S&P SmallCap 600 after the close of trading on Monday, October 3.

  • MannKind (Nasdaq: MNKD) $. MannKind continuing lower from last Friday after disclosing: On September 14, 2016, MannKind Corporation (the “Company”) received a letter from The Nasdaq Stock Market (the “Nasdaq Letter”) indicating that for 30 consecutive business days the Company’s common stock had not maintained a minimum closing bid price of at least $1.00 per share (the “Minimum Bid Price Requirement”) as required by Nasdaq Listing Rules.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Special Reports

Related Entities

Standard & Poor's

Add Your Comment